It was observed that as opposed to the NIH-OVCAR3 cells, ATM was more likely to be amplified or show higher mRNA expression in ovarian cancers (8%) compared to 2% with deep deletions (or low mRNA levels). This evidence concerns the gene ATM and ovarian carcinoma.